AtriCure, Inc. (ATRC)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-06

Key Insights

The filing shows Q1 2026 results for AtriCure with segment reporting across multiple product categories (Openheart, Minimally Invasive, Pain Management, Appendage Management) in both US and international markets, indicating a diversified revenue base across geographies.
The company maintained debt facilities including an ABL (Asset-Based Lending) facility and secured debt arrangements, with detailed rate structures showing exposure to SOFR-based pricing, suggesting active management of liquidity and financing obligations.
Intangible assets including technology-based patents and contingent consideration liabilities are tracked, indicating prior acquisitions with earn-out provisions that could impact future cash flows and financial results.
International operations span Europe, Asia-Pacific, and other regions, with segment-level reporting suggesting material non-US revenue streams that expose the company to foreign exchange and regulatory risks.

Insider Trading Filed: 2026-03-16

Key Insights

Vinayak Doraiswamy, the Chief Scientific Officer of AtriCure, Inc., sold 5,000 shares of the company's common stock at an average price of $29.83 per share.
This transaction represents a small portion of Doraiswamy's overall beneficial ownership, which remains at 96,875 shares following the reported sale.
Insider selling can sometimes signal management's views on the company's future prospects, but a single transaction of this size is not necessarily a significant event on its own.

Insider Trading Filed: 2026-03-12

Key Insights

The reporting person, Robert S. White, has exercised 10,000 non-qualified stock options in AtriCure, Inc. (ATRC) at an exercise price of $14.99 per share.
The exercise of these options has increased White's direct beneficial ownership of ATRC common stock to 122,174 shares.
The exercise of these options was made pursuant to a contract, instruction or written plan, suggesting a planned transaction.

Insider Trading Filed: 2026-03-09

Key Insights

The reporting person, Michael H. Carrel, who is the President, CEO, and Director of AtriCure, Inc., has made two separate gifts of 5,000 and 1,000 shares of the company's common stock to his children and sibling, respectively.
Carrel continues to hold a significant direct ownership stake in AtriCure, with 778,498 shares, and also has indirect beneficial ownership of an additional 17,560 shares through his children and parents.
The reporting of these insider transactions provides insight into Carrel's confidence in the company and his alignment with shareholder interests through his personal holdings.

Annual Report Filed: 2026-02-19

Key Insights

AtriCure's revenue growth in the medical devices segment has been steadily increasing, indicating continued strong demand for their products.
The company's operating and financing lease liabilities have increased over the years, suggesting potential expansion of facilities and equipment to support business growth.
AtriCure has maintained a healthy balance sheet with a mix of cash, money market funds, and access to a revolving credit facility, providing financial flexibility.

Current Report Filed: 2026-01-12

Key Insights

AtriCure has extended its credit agreement by 3 years, providing additional financial flexibility to support its working capital needs and general corporate purposes.
The credit agreement now has reduced interest rates on the loans under the ABL Facility, improving AtriCure's cost of capital.
The removal of the minimum utilization financial covenant provides AtriCure more operational freedom in managing its borrowing activities under the credit facility.

Insider Trading Filed: 2026-01-02

Key Insights

Douglas J. Seith, the Chief Operating Officer of AtriCure, Inc. (ATRC), acquired 257 shares of the company's common stock through the 2018 Employee Stock Purchase Plan on December 31, 2025.
The shares were purchased at a discounted price of $27.37 per share, which is 85% of the closing price on the first trading day of the applicable offering period.
This insider purchase suggests Seith's confidence in the company's outlook and aligns his interests with those of shareholders.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.